Medicare's First Negotiated Drug Prices Launch January 2026, Delivering $1.5 Billion in Patient Savings
核心洞察
Medicare (搜索)'s first negotiated drug prices for 10 high-cost medications will take effect January 1, 2026, reducing patient out-of-pocket spending by an estimated $1.5 billion annually.
The negotiated prices represent significant discounts, with Januvia dropping 79% from $527 to $113 for a 30-day supply and Eliquis decreasing 56% from $521 to $231.
The program will expand progressively, with 15 additional drugs including blockbuster diabetes medications entering negotiation for 2027 implementation, ultimately covering 20 drugs annually by 2029.
The first Medicare (搜索)-negotiated prescription drug prices will debut January 1, 2026, marking a historic milestone in healthcare cost reduction that will save Medicare beneficiaries an estimated $1.5 billion in annual out-of-pocket expenses. The program, established under the Inflation Reduction Act of 2022, targets 10 high-cost, brand-name medications that collectively accounted for $46.4 billion in Medicare Part D spending in 2022.
Substantial Price Reductions Across Key Therapeutic Areas
The negotiated prices deliver substantial savings across medications treating serious chronic conditions. Januvia, a diabetes medication used by approximately 850,000 Medicare (搜索) beneficiaries, will cost $113 for a 30-day supply in 2026, representing a 79% reduction from the 2023 list price of $527. Medicare's Part D program spent more than $4 billion on Januvia in 2023 alone.
Eliquis, an anticoagulant used by nearly 4 million Medicare (搜索) beneficiaries for blood clot prevention and treatment, will see its 30-day supply price drop 56% to $231, down from $521 in 2023. Medicare expenditures on Eliquis reached nearly $18.3 billion in 2023, making it one of the program's most costly medications.
The complete list of medications receiving negotiated prices includes Eliquis for blood clot prevention, Enbrel for rheumatoid arthritis and psoriasis, Entresto for heart failure, Farxiga for diabetes and heart failure, insulin products Fiasp and NovoLog, Imbruvica for blood cancers, Januvia for diabetes, Jardiance for diabetes and heart failure, Stelara for autoimmune conditions, and Xarelto for blood clot prevention.
Program Structure and Long-term Impact
The negotiated prices represent a minimum 38% discount from 2023 list prices and will remain in effect as long as the medications remain in the program. Centers for Medicare & Medicaid Services (搜索) will publish updated prices annually for each drug continuing in the negotiation program.
If these negotiated prices had been implemented in 2023, Medicare (搜索) would have saved an estimated $6 billion, representing approximately 22% savings on the 10 selected drugs, including rebates and other payments. The medications treat conditions affecting millions of Americans, including cancer, diabetes, blood clots, heart failure, autoimmune conditions, and chronic kidney disease.
Expanding Scope and Future Implementation
The program will expand systematically in subsequent years. Negotiations for 15 additional Part D medications, including blockbuster diabetes drugs, are currently underway throughout 2025, with new prices taking effect in 2027. These 15 drugs account for approximately $41 billion in Part D spending and are used by roughly 5.3 million beneficiaries.
Beginning in 2027, the program will expand to include both Part B medications, typically administered intravenously or in healthcare facilities, and Part D drugs. The number of negotiated medications will increase to 20 annually starting in 2027, with those reduced prices becoming effective in 2029.
Broad Beneficiary Access and Plan Requirements
All eligible Medicare (搜索) beneficiaries will have access to the negotiated prices, with mandatory inclusion requirements for Medicare Advantage plans offering drug coverage and stand-alone Part D plans for original Medicare enrollees. The cumulative nature of the program means the total number of medications with negotiated prices will continue growing over time.
According to a December 2024 AARP (搜索) survey of more than 1,000 adults aged 50 and older, 96% of respondents indicated the government should do more to lower prescription prices, with more than 80% reporting regular prescription medication use. The survey data underscores the significant demand for prescription drug cost relief among Medicare (搜索)-eligible populations.